| 6:30 am - 6:00 pm |
Registration Open
BCC: Charles Street Lobby |
| 7:00 am - 9:00 am |
SVS Women's Networking Breakfast
Renaissance Harborplace Hotel: Federal Hill
Join the SVS Committee on Women's Issues for the 6th Annual Women's
Networking Breakfast. This event provides the opportunity for female SVS
members to exchange ideas and discuss new initiatives for the committee. |
| 7:00 am - 8:30 am |
Concurrent Breakfast Sessions |
|
Infrainguinal Endovascular Therapy: State of the Art 2007
Supported by an educational grant from Cordis Endovascular,
a Johnson & Johnson Company
BCC: Ballroom IV
Moderator: Daniel G. Clair, MD
Cleveland Clinic Foundation, Cleveland, Ohio
At the end of this session, participants should be able to:
- Understand the differences between varied
forms of treatment of infrainguinal disease.
- Recognize differing outcomes for alternate
forms of treatment of infrainguinal disease.
- Determine disease patterns that may predispose to improved
outcomes for treating lower extremity occlusive disease.
7:00 am
Angioplasty
Evan C. Lipsitz, MD, Montefiore Medical Center, Bronx, N.Y.
7:10 am
Atherectomy
James F. McKinsey, MD,
Columbia University Medical Center, New York, N.Y.
7:20 am
Stents and Medicated Stents
Luke K. Marone, MD, University of Pittsburgh, Pittsburgh, Pa.
7:40 am
Stent Grafts
Patrick Geraghty, MD,
Washington University School of Medicine, St. Louis, Mo.
7:50 am
Limitations of Endovascular Therapy: When Surgery is Still the Best Option
Michael S. Conte, MD, Brigham and Women's Hospital, Boston, Mass.
8:00 am
Current Trials
George H. Meier, MD, Vascular & Transplant Specialist, Norfolk, Va.
8:10 am
Making Sense of the Options
Donald L. Jacobs, MD, St. Louis University Medical Center, St. Louis, Mo.
8:20 am
Panel Discussion: Questions and Answers
Stent Graft Repair for Thoracic Aortic Pathology
Supported by an educational grant from W.L. Gore & Associates, Inc.
BCC: Rooms 309/310
Moderator: Ronald M. Fairman, MD
Hospital of the University of Pennsylvania, Philadelphia, Pa.
At the end of this session, participants should be able to:
- Recognize the complications associated
with endovascular repair of the thoracic aorta.
- Be updated on the status of the only FDA-approved
thoracic endograft: the Gore TAG device.
- Be familiar with the ongoing clinical trials of thoracic endografting.
- Have an understanding of TEVAR practice
patterns outside the US experience.
- Recognize the important issues that may
develop when following patients after TEVAR.
- Be familiar with how the technology is evolving.
7:00 am
FDA Approved Thoracic Endografts and Current
Status of Thoracic Endograft Clinical Trials
Ross Milner, MD, Emory University Hospital, Atlanta, Ga.
7:12 am
Complications Associated with Thoracic Endografting
Alan B. Lumsden, MD, Methodist DeBakey Heart Center, Houston, Texas
7:24 am
Practice Patterns and Trends Overseas
Where There is Little Device Restriction
Frank J. Criado, MD, Union Memorial Hospital, Baltimore, Md.
7:36 am
Strategies for Reducing Perioperative Stroke and Paraplegia
Ronald M. Fairman, MD
Hospital of the University of Pennsylvania, Philadelphia, Pa.
7:48 am
Guidelines for Following Patients After Thoracic Stent Graft Repair:
Sac Regression, Endoleaks, and Secondary Procedures
Manish Mehta, MD, The Vascular Group, PLLC, Albany, N.Y.
8:00 am
The Future: Hybrids and Ascending Procedures
Mark A. Farber, MD, UNC Vascular Surgery, Chapel Hill, N.C.
8:12 am
Panel Discussion: Questions and Answers |
| 8:30 am - 9:50 am |
SVS Plenary Session
BCC: Ballrooms I/II |
|
Moderators:
Roy K. Greenberg, MD
Cleveland Clinic Foundation, Cleveland, Ohio
Robert M. Zwolak, MD
Dartmouth-Hitchcock Medical Center, Lebanon, N.H.
At the end of this session, participants should be able to:
- Discuss the methodology, results, and conclusions
of the research presented in vascular health.
- Gain knowledge of new technology for diagnosis
and treatment of vascular disease.
8:30 am
S16. Duplex Derived Grey-Scale Median (GSM) of
Femoral/Popliteal Arterial Segments: A Novel Predictor
of Success or Failure for Subintimal Dissections
8:46 am
S17. Subintimal Angioplasty: Experience in
the Treatment of 648 Chronic Total Occlusions
9:02 am
S18. Infrapopliteal Balloon Angioplasty for
the Treatment of Chronic Occlusive Disease:
Intermediate-Term Results of a Contemporary Series
9:18 am
S19. A Randomized Trial to Assess Long-term
Outcome of Prophylactic Coronary Revascularization
in Cardiac High-Risk Patients Undergoing Major
Vascular Surgery: DECREASE-V Pilot Study
9:34 am
S20. Insurance Status Predicts Access to
Care and Outcomes of Vascular Disease |
| 9:50 am - 10:20 am |
Coffee Break
BCC: Halls A-C |
| 10:00 am - 4:00 pm |
Exhibits Open
BCC: Halls A-C |
| 10:20 am - 11:40 am |
SVS Plenary Session
BCC: Ballrooms I/II |
|
Moderators:
Richard P. Cambria, MD
Massachusetts General Hospital, Boston, Mass.
Nicholas J. Morrissey, MD
Columbia Presbyterian Hospital, New York, N.Y.
At the end of this session, participants should be able to:
- Discuss the methodology, results, and conclusions
of the research presented in vascular health.
- Gain knowledge of new technology for diagnosis
and treatment of vascular disease.
10:20 am
S21. LATE-BREAKING CLINICAL TRIAL:
Pivotal Results of the Medtronic Vascular Talent™
Thoracic Stent Graft System for Patients with Thoracic
Aortic Disease. The VALOR Trial
10:36 am
S22. Technical Factors Affecting Autogenous Vein
Graft Failure: Observations from a Large Multicenter Trial
10:52 am
S23. Unilateral Iliac Artery Occlusive Disease: Long-term
Results of a Randomized Multicenter Trial Examining Direct
Revascularization vs. Crossover Bypass
11:08 am
S24. Effect of Adding Clopidogrel to Aspirin on the
Success of Below Knee Arterial Bypass Grafts.
A Randomized Placebo Controlled Study
11:24 am
S25. Totally Endovascular Thoracoabdominal Aneurysm Repair |
| 11:40 am - 12:25 pm |
SVS Presidential Address
BCC: Ballrooms I/II
K. Craig Kent, MD
New York Presbyterian Hospital, New York, N.Y. |
| 12:25 pm - 2:00 pm |
SVS Member Business Luncheon
BCC: Ballroom IV |
| 12:25 pm - 2:00 pm |
SVS Medical Student/General Surgery Resident
Scholarship Recipient Lunch
BCC: Room 314 |
| 12:25 pm - 2:00 pm |
Non-Member Box Luncheon
BCC: Halls A-C |
| 2:00 pm - 3:30 pm |
Concurrent Breakout Sessions |
|
Session F1: Joint European Society for Vascular Surgery/
Society for Vascular Surgery Program –
European Perspective on Controversies in Vascular Surgery
BCC: Rooms 307/308
Moderators:
Enrico Ascher, MD
Maimonides Medical Center, Brooklyn, N.Y.
Henrik Sillesen, MD, DMSc
University of Copenhagen, Copenhagen, Denmark
At the end of this session, participants should be able to:
- Interpret clinical practice of recent carotid trials.
- Know when to stent in patients with acute aortic dissection.
- Evaluate if surgical training be supplemented by use of simulators.
- Assess how much follow-up is really necessary after EVAR.
2:00 pm
Management of Carotid Disease – the European Perspective
A. Ross Naylor, MD, FRCS, MBCHB
University of Leicester, United Kingdom
2:18 pm
Stenting in Acute Dissection
Jan Brunkwall, MD, PhD, University of Cologne, Germany
2:36 pm
Training Simulators in Open Surgery
John Wolfe, MD, MB BS, FRCS, MS
St. Mary’s Hospital, London, United Kingdom
2:54 pm
Follow-up After EVAR – What Is Really Necessary?
Jan Blankensteijn, MD, PhD
Radboud University Nijmegen Medical Centre, The Netherlands
3:12 pm
Panel Discussion: Questions and Answers
Session F2: Peripheral Vascular Surgical Society Papers
BCC: Rooms 318-323
Moderators:
Ruth L. Bush, MD
Baylor College of Medicine, Houston, Texas
Allen D. Hamdan, MD
Beth Israel-Deaconess Medical Center, Boston, Mass.
At the end of this session, participants should be able to:
- Understand the choices for imaging of
vascular diseases and their limitations.
Appreciate the role of open and endovascular
procedures for carotid therapy.
- Review the current status and outcomes of
treatment for thoracic and abdominal aneurysms.
- Understand the management options and limitations
for treatment of lower extremity occlusive disease.
- Appraise novel therapies for vascular disease.
2:00 pm
PVSS1. Eversion Carotid Endarterectomy: A Versatile
and Durable Procedure. An Analysis of 7,781 Procedures
2:15 pm
PVSS2. Increased Aortic Arch Calcification in Patients
Over 75 Years: Implications for Carotid Angioplasty and
Stenting in Elderly Patients
2:30 pm
PVSS3. Traumatic Pseudoaneurysms of the
Head and Neck: Early Endovascular Intervention
2:45 pm
PVSS4. Association Between Minor and Major
Surgical Complications after Carotid Endarterectomy:
Results of the New York Carotid Artery Surgery Study
3:00 pm
PVSS5. Expectant Post-operative Lumbar
Spinal Drainage after Thoracic Aortic Endografts
3:15 pm
PVSS6. Strategies to Improve Spinal Cord Ischemia
in Endovascular Thoracic Aortic Repair: Outcomes of
a Prospective Cerebrospinal Fluid Drainage Protocol
Session F3: Restenosis After Vascular Intervention:
Insights from Contemporary Translational Research
BCC: Rooms 309/310
Moderator: Michael S. Conte, MD
Brigham and Women's Hospital, Boston, Mass.
At the end of this session, participants should be able to:
- Understand the rationale and current clinical status
of drug and device technologies designed to reduce
restenosis following vascular reconstructions.
- Understand the potential benefits, failure modes
and complications for drug eluting stent applications
in peripheral arteries.
- Understand the nature of novel approaches being
tested for the prevention of vein bypass and AV access failure.
2:00 pm
Perspectives on Molecular Targets and
Drug Development for Intimal Hyperplasia
Alexander W. Clowes, MD, University of Washington, Seattle, Wash.
2:12 pm
Clinical Development of Nitric Oxide-Related Therapeutics
Edith Tzeng, MD, University of Pittsburgh, Pittsburgh, Pa.
2:24 pm
Drug-Eluting Stents and Their Application to Peripheral Arteries
Lewis B. Schwartz, MD, Abbott Laboratories, Abbott Park, Ill.
2:36 pm
Drug Eluting Stents in the Periphery: Will They Work?
Renu Virmani, MD, CVPath,
International Registry of Pathology, Gaithersburg, Md.
2:48 pm
Molecular Therapies to Prevent Vein Graft Failure:
Lessons and Directions
Michael S. Conte, MD
Brigham and Women's Hospital, Boston, Mass.
3:00 pm
Novel Approaches to Prevent AV Access Failure
Ted R. Kohler, MD, VA Puget Sound Health Care System, Seattle, Wash.
3:12 pm
Panel Discussion: Questions and Answers
|
| 3:00 pm - 6:00 pm |
Association of Chairs in Vascular Surgery Meeting
BCC: Ballroom IV |
|
Topic 1: Compensation and Incentive Plans
Moderator: Peter F. Lawrence, MD
UCLA Medical Center, Los Angeles, Calif.
At the end of this session, participants should be able to:
- Plan compensation to reward efforts of individual
surgeons caring for patients or involved in other related activities.
- Devise a better way to work with other specialties
in the care of the Vascular Patient.
- Structure their practice to have the best
outcomes in different areas of vascular surgery.
Compensation of vascular surgeons is changing rapidly as demand
for services outstrips supply of new trainees. Clinical activity and non
income generating tasks are variable among members of a division. Is
there a rational and equitable way of compensating individuals in a
Vascular Department?
3:00 pm
Benchmarking of Clinical Activity Is Essential in the Development of a
Fair Compensation Plan. Results of a SVS National Survey.
Jack L. Cronenwett, MD
Dartmouth-Hitchcock Medical Center, Lebanon, N.H.
3:08 pm
Recent Vascular Surgery Hiring Practices
in the United States. An SCVS Survey.
Audra Duncan, MD, Mayo Clinic, Rochester, Minn.
3:14 pm
A Large Medical Faculty Group: The Imperative of a Structured
Incentive Plan, Legal Ramifications and How to Fund It.
Marshall W. Webster, MD
University of Pittsburgh Medical Center, Pittsburgh, Pa.
3:24 pm
Compensation and Incentive Plan of an Academic Vascular
Division. Can We Strike a Balance Between Income Generating
Activity and Academic Pursuits?
Michel S. Makaroun, MD,
University of Pittsburgh School of Medicine, Pittsburgh, Pa.
3:32 pm
Compensation Plan in Private Practice.
Is the Partnership Tract Still a Viable Option?
Russell H. Samson, MD, Sarasota, Fla.
3:40 pm
Panel Discussion: Questions and Answers
Topic 2: Cardiac Surgery, Cardiology and Vascular Surgery
Moderator: Jack L. Cronenwett, MD
Dartmouth-Hitchcock Medical Center, Lebanon, N.H.
Cardiologists want to treat peripheral vascular problems.
Cardiac surgeons are embracing endovascular work. Is
the field getting crowded? What is the optimal arrangement?
4:10 pm
The Effect of a Service Line Implementation on an Academic
Vascular Division. It Works!
William D. Turnipseed, MD, Central AR Vascular Surgery, Madison, Wis.
4:17 pm
We Can Work with the Cardiologists and Benefit too!
John Martin, MD, Anne Arundel Medical Center, Annapolis, Md.
4:24 pm
The Challenges Facing Cardiac Surgeons.
Can Vascular Surgeons Help or Are They in the Way?
Irving L. Kron, MD, UVA Health System, Charlottesville, Va.
4:33 pm
Cardiac and Vascular Surgery Have a Common Destiny:
Back to the Future!
Alan B. Lumsden, MD, Methodist DeBakey Heart Center, Houston, Texas
4:40 pm
Panel Discussion: Questions and Answers
Topic 3: Subspecialization in Vascular Surgery
Moderator: Michel S. Makaroun, MD
University of Pittsburgh School of Medicine, Pittsburgh, Pa.
The scope of vascular surgery is ever expanding, from thoracoabdominal
aneurysms to tibial reconstructions, dialysis access to non invasive vascular
diagnosis and venous procedures to endovascular aneurysm repair.
Can all members of a vascular department do it all and be good at it?
Are there any solutions?
5:15 pm
Credentialing Depends on Volume and Outcomes.
How does it Apply to Vascular Surgery?
Daniel G. Clair, MD, Cleveland Clinic Foundation, Cleveland, Ohio
5:22 pm
A Modern Vascular Department Must Develop
Areas of Concentration to Provide Expert Care.
R. Clement Darling, MD, The Vascular Group, PLLC, Albany, N.Y.
5:30 pm
Panel Discussion: Questions and Answers |
| 3:30 – 4:00 pm |
Coffee Break
BCC: Halls A-C |
| 4:00 pm - 5:30 pm |
Concurrent Breakout Sessions
BCC: Rooms 307/308 |
|
Session F4: Joint Society for Vascular Medicine and Biology/
Society for Vascular Surgery Program –
Medical Therapies All Vascular Specialists Must Know About
Moderators:
Richard P. Cambria, MD
Massachusetts General Hospital, Boston, Mass.
Michael R. Jaff, DO
Massachusetts General Hospital, Boston, Mass.
At the end of this session, participants should be able to:
- Understand the role of pharmacotherapies for intermittent claudication.
- Assess and differentiate the use of specific
antithrombotic agents in vascular disease.
- Define appropriate antiplatelet strategies in
Peripheral Arterial Disease (PAD).
- Select appropriate lipid-lowering therapies for
carotid artery disease and for patients with systemic atherosclerosis.
4:00 pm
Pharmacologic Therapy and Exercise of Intermittent Claudication –
Now and in the Future
Tracie C. Collins, MD, MPH,
University of Minnesota Physicians, Minneapolis, Minn.
4:15 pm
Beyond Heparin—Anticoagulants for Venous Thrombosis
Thomas Wakefield, MD
University of Michigan Medical Center, Ann Arbor, Mich.
4:30 pm
Antiplatelet Therapy in Peripheral Vascular Disease –
Optimal Strategies
Paul Gurbel, MD, Sinai Health System, Baltimore, Md.
4:45 pm
Carotid-Specific Lipid Lowering: What Does the Data Show?
Glenn LaMuraglia, MD, Massachusetts General Hospital, Boston, Mass.
5:00 pm
Lipid Lowering Therapy in Patients with Systemic
Atherosclerosis – The Obligation of the Vascular Specialist
Steven M. Dean, DO, The Ohio State University, Columbus, Ohio
5:15 pm
Panel Discussion: Questions and Answers
Session F5: Peripheral Vascular Surgical Society Papers
BCC: Rooms 318-323
Moderators:
Vikram S. Kashyap, MD
Cleveland Clinic Foundation, Cleveland, Ohio
David J. Minion, MD
University of Kentucky College of Medicine, Lexington, Ky.
At the end of this session, participants should be able to:
- Understand the choices for imaging of
vascular diseases and their limitations.
- Appreciate the role of open and endovascular
procedures for carotid therapy.
- Review the current status and outcomes of
treatment for thoracic and abdominal aneurysms.
- Understand the management options and limitations
for treatment of lower extremity occlusive disease.
- Appraise novel therapies for vascular disease.
3:50 pm
Von Liebig Award Report
James Laredo
Georgetown University Hospital, Washington, D.C.
4:00 pm
PVSS7. A 9-Year Experience with Endovascular Thoracic
Aortic Repair: Long-Term Follow-Up and Lessons Learned
4:15 pm
PVSS8. Growth Predictors of Small Abdominal Aortic Aneurysms.
Possible Consequences for Small Aneurysm Treatment Strategies
4:30 pm
PVSS9. Should Endovascular Repair Treatment Threshold
be Expanded for Small Abdominal Aortic Aneurysms?
4:45 pm
PVSS10. A Meta-analysis of Endovascular Repair
of Ruptured Abdominal Aortic Aneurysms
5:00 pm
PVSS11. Managing Iliac Artery Occlusive Disease
During Endovascular Aneurysm Repair: The Use of Conduits
5:15 pm
PVSS12. Device Specific Aneurysm Sac Morphology
Following EVAR: Evaluation of Contemporary Graft Materials
Session F6: Research Forum
BCC: Rooms 309/310
Moderator: Larry W. Kraiss, MD
University of Utah Medical Center, Salt Lake City, Utah
At the end of this session, participants should be able to:
- Discuss the methodology, results, and conclusions
of the research presented in vascular health.
- Gain knowledge of new technology for
diagnosis and treatment of vascular disease.
4:00 pm
R1. Increased Notch Pathway Expression During
Vein Graft Adaptation in Young Adult but not Aged Rats
4:10 pm
R2. Focal Adhesion Kinase Mediates the Frequency
and Depth of Vascular Smooth Muscle Invasion in a
Novel Three-Dimensional Assay
4:20 pm
R3. The Molecular Chaperone Heat Shock
Protein 90 (Hsp90): A Novel Target for Regulating
Smooth Muscle Cell (SMC) Growth in Vascular Injury
4:30 pm
R4. Selective G-protein Activation Is Required for
Urokinase Induced Smooth Muscle Cell Migration
4:40 pm
R5. Iodinated Contrast Induced Renal Injury Is
Exaggerated in a Rat Model of Genetic
Non-Insulin-Dependent-Diabetes Mellitus and Obesity
4:50 pm
Abstract Withdrawn
5:00 pm
R7. Effect of Estrogen and Progesterone on Matrix
Metalloproteinase Gene Expression and Function
in Human Aortic Vascular Smooth Muscle Cells
5:10 pm
R8. Collateral Development in Lower
Limb Ischemia Is Impaired by Diabetes
|
Members Only Login
Print this page